
I-Mab IMAB
Quarterly report 2025-Q2
added 02-21-2026
I-Mab Total Assets 2011-2026 | IMAB
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets I-Mab
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 6.33 B | 1.74 B | 2.38 B | 1.03 B | - | - | - | - | - | - |
All numbers in CNY currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.33 B | 1.03 B | 2.87 B |
Quarterly Total Assets I-Mab
| 2025-Q2 | 2024-Q4 | 2023-Q4 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 2.61 B | 4.07 B | - | 4.99 B | - | 5.6 B | - | - | - | 6.33 B | 4.3 B | - | - | 1.74 B | - | - | - | 2.38 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in CNY currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.33 B | 1.74 B | 4 B |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
396 M | - | 1052.0 % | $ 415 M | ||
|
Autolus Therapeutics plc
AUTL
|
783 M | $ 1.68 | 2.44 % | $ 429 M | ||
|
Acer Therapeutics
ACER
|
11.6 M | - | 2.71 % | $ 14 M | ||
|
Acasti Pharma
ACST
|
72 M | - | 4.01 % | $ 150 M | ||
|
Adverum Biotechnologies
ADVM
|
180 M | - | - | $ 86.2 M | ||
|
Kamada Ltd.
KMDA
|
372 M | $ 8.81 | 1.73 % | $ 260 M | ||
|
Aeglea BioTherapeutics
AGLE
|
778 M | - | - | $ 1.01 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M | ||
|
Adagene
ADAG
|
89.3 M | $ 3.26 | 0.62 % | $ 183 M | ||
|
Alterity Therapeutics Limited
ATHE
|
41.4 M | $ 3.28 | -2.62 % | $ 7.89 B | ||
|
Evogene Ltd.
EVGN
|
39.9 M | $ 0.81 | -9.28 % | $ 27.9 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
14.8 M | - | -18.52 % | $ 27.3 M | ||
|
Akero Therapeutics
AKRO
|
826 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
279 M | - | 0.23 % | $ 488 M | ||
|
Nymox Pharmaceutical Corporation
NYMX
|
654 K | - | -19.68 % | $ 18.4 M | ||
|
Albireo Pharma
ALBO
|
302 M | - | -0.23 % | $ 916 M | ||
|
Aptorum Group Limited
APM
|
16.1 M | $ 0.79 | -1.29 % | $ 4.31 M | ||
|
Alpine Immune Sciences
ALPN
|
287 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
119 M | - | 4.14 % | $ 49.1 M | ||
|
XTL Biopharmaceuticals Ltd.
XTLB
|
8.55 M | $ 0.88 | -1.43 % | $ 442 M | ||
|
Allena Pharmaceuticals
ALNA
|
34.8 M | - | 3.16 % | $ 1.9 M | ||
|
Ampio Pharmaceuticals
AMPE
|
5.74 M | - | -11.43 % | $ 502 K | ||
|
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | ||
|
Applied Molecular Transport
AMTI
|
107 M | - | - | $ 10.1 M | ||
|
Aptose Biosciences
APTO
|
10.1 M | - | -45.71 % | $ 1.2 M | ||
|
Aravive
ARAV
|
62.2 M | - | -13.39 % | $ 1.45 M | ||
|
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - | ||
|
Ascendis Pharma A/S
ASND
|
1.3 B | $ 224.42 | -2.52 % | $ 5 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
66.7 M | - | - | $ 26.5 M | ||
|
Arena Pharmaceuticals
ARNA
|
785 M | - | -6.81 % | $ 3.04 B | ||
|
Athersys
ATHX
|
60.2 M | - | 3.77 % | $ 22.4 M | ||
|
AVROBIO
AVRO
|
101 M | - | 1083.1 % | $ 745 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
104 M | $ 4.13 | 0.12 % | $ 352 M | ||
|
Aeterna Zentaris
AEZS
|
35.1 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
12 M | - | -10.17 % | $ 12.2 K | ||
|
Aytu BioScience
AYTU
|
124 M | $ 2.36 | 2.27 % | $ 14.8 M | ||
|
Aptinyx
APTX
|
66.7 M | - | -39.0 % | $ 4.57 M | ||
|
AstraZeneca PLC
AZN
|
104 B | - | - | $ 96.9 B | ||
|
Aridis Pharmaceuticals
ARDS
|
14.7 M | - | 17.91 % | $ 11.1 M | ||
|
Brickell Biotech
BBI
|
11.6 M | - | -5.38 % | $ 6.06 M | ||
|
Codexis
CDXS
|
149 M | $ 1.17 | -0.85 % | $ 85.9 M | ||
|
Athira Pharma
ATHA
|
58.8 M | - | - | $ 269 M | ||
|
BioNTech SE
BNTX
|
22.5 B | $ 110.12 | -0.28 % | $ 27.2 B | ||
|
Amneal Pharmaceuticals
AMRX
|
3.5 B | $ 14.49 | -0.75 % | $ 4.48 B | ||
|
AIkido Pharma
AIKI
|
47.1 M | - | 1.93 % | $ 17.4 M | ||
|
CureVac N.V.
CVAC
|
1.16 B | - | - | $ 867 M |